To review and evaluate reimbursable point-of-care testing devices yielding immediate results, other than glucometers, that are available to evaluate and monitor diabetes and its complications and to describe how pharmacists may use these devices.
DATA SOURCES:
A MEDLINE search (1966-March 2003) was performed using the following search terms: point-of-care systems, clinical diabetes monitoring, decision support systems, glycosylated hemoglobin, and microalbumin. Pertinent company and product Web sites and customer service departments were accessed for information about point-of-care devices and supplies.
STUDY SELECTION AND DATA EXTRACTION:
All descriptive, evaluative, and comparative articles and product information were reviewed, and relevant information was included.
DATA SYNTHESIS:
Diabetes mellitus is a complex, chronic metabolic disease that is a challenging management problem and requires routine monitoring for disease control and screening for complications. Point-of-care tests are available to monitor hemoglobin A1c, glucose, fructosamine, ketones, lipid profiles, urinary microalbumin concentrations, and alanine aminotransferase concentrations. Many of these tests are Clinical Laboratory Improvement Amendments (CLIA)—waived and, therefore, practical for pharmacists to use in a variety of settings. Tests for measuring sensation are also discussed. Pharmacists should consider each of these tests in the establishment of a comprehensive diabetes care service.
CONCLUSIONS:
The availability of many new point-of-care testing methods creates new opportunities for pharmacists to monitor drug therapy and screen for complications in patients with diabetes. Reimbursement is possible since many of these tests are CLIA-waived.
American Diabetes Association. Position statement on the economic costs of diabetes in the U.S. in 2002. Diabetes Care2003; 26 (Suppl 1): 917–32.
2.
MensingCBoucherJCypressMWeingerKMulcahyKBartaP, National standards for diabetes self-management education. Diabetes Care2000; 23: 682–9.
3.
Coast-SeniorEAKronerBAKellyCLTrilliLE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother1998; 32: 636–41. DOI 10.1345/aph.17095
4.
HogueVWBabamotoKSJacksonTBCohenLBLaitinenDL. Pooled results of community pharmacy—based diabetes education programs in underserved communities. Diabetes Spectrum2003; 16: 129–33.
5.
CranorCWBuntingBAChristensenDB. The Asheville project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc2003; 43: 173–84.
6.
GongCHassonNKLumBL. Impact of a diabetes disease management clinic on the total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Managed Care Pharm1999; 5: 511–5.
7.
NauDPPonteCD. Effects of a community pharmacist—based diabetes patient management program on intermediate clinical outcome measures. J Managed Care Pharm2002; 8: 48–53.
8.
KellyCRodgersPT. Implementation and evaluation of a pharmacist-managed diabetes service. J Managed Care Pharm2000; 6: 448–93.
9.
SczupakCAConradWF. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm1977; 34: 1238–42.
10.
JaberLAHalapyHFernetMTummalapalliSDiwakaranH. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother1996; 30: 238–43.
11.
RosenthalWM. Establishing a pharmacy-based laboratory service. J Am Pharm Assoc2000; 40: 146–52, 154–6.
12.
SacksDBBrunsDEGoldsteinDEMaclarenNKMcDonaldJMParrottM. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem2002; 48: 3.436–72.
13.
Package insert. DCA 2000. Elkhart, IN: Bayer Corporation, October 2000.
14.
Package insert. Cholestech GDX. Hayward, CA: Cholestech, June 2002.
15.
Metrika's A1cNow Single Use A1C test. www.A1cnow.com (accessed 2003 Jul 30).
16.
BryLChenPCSacksDB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem2001; 47: 153–63.
GoldsteinDELittleRRLorenzRAMaloneJINathanDPetersonCM. Tests of glycemia in diabetes. Diabetes Care1995; 19: 896–909.
19.
SheetzMJKingGL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA2002; 288: 2579–88.
20.
LittleRRRohlfingCLWiedmeyerHMMyersGLSacksDBGoldsteinDE. The national glycohemoglobin standardization program: A five year progress report. Clin Chem2001; 47: 1985–92.
21.
LittleRR. Recent progress in glycohemoglobin testing. Diabetes Care2000; 23: 265–6.
WeykampCWPendersTJMuskietFAVan der SlikW. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem1993; 39: 1717–23.
American Diabetes Association. Position statement on diabetic nephropathy. Diabetes Care2003; 26 (Suppl 1): 94–8.
30.
MogensenCEKeaneWFBennettPHJerumsGParvingHPassaP, Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet1995; 346: 1080–4.
31.
ZelmanovitzTGrossJLOliveiraJRPaggiATatschMAzevedoMJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care1997; 20: 516–9.
32.
MogensenCEVestboEPoulsenPLChristiansenCDamsgaardEMEisjaerH, Microalbuminuria and potential confounders: A review and some observations on variability of urinary albumin excretion. Diabetes Care1995; 18: 572–81.
33.
Package insert. Chemstrip Micral dip and read immunoassay for the semi-quantitative determination of microalbuminuria. Indianapolis, IN: Roche Diagnostic Corporation, 2003.
MogensenCEVibertiGCPeheimEKutterDHasslacherCHofmannW, Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria. Diabetes Care1997; 20: 1642–6.
40.
ParsonsMNewmanDJPugiaMNewallRGPriceCP. Performance of a reagent strip device for quantitation of the urine albumin: Creatinine ratio in a point of care setting. Clin Nephrol1999; 51: 220–7.
41.
LeFlochJPMarreMRodierMPassaP. Interest of Clinitek Microalbumin in screening for microalbuminuria: Results of a multicentre study in 302 diabetic patients. Diabetes Metab2001; 27: 36–9.
42.
PugiaMJLottJALukeKEShihabiZKWiansFHPhillipsL. Comparison of instrument-read dipsticks for albumin and creatinine in urine with visual results and quantitative methods. J Clin Lab Anal1998; 12: 280–4.
43.
WallaceJFPugiaMJLottJALukeKEShihabiZKSheehanM, Multisite evaluation of a new dipstick for albumin, protein, and creatinine. J Clin Lab Anal2001; 15: 231–5.
44.
Package insert. ALT (GPT) alanine aminotransferase test cassette. Hayward, CA: Cholestech LDX, 2002.
45.
Koda-KimbleMACarlisleBA. Diabetes mellitus. In: Koda-KimbleMAYoungLY, eds. Applied therapeutics: The clinical use of drugs. 7th ed.Philadelphia: Lippincott Williams & Wilkins, 2001: 4849–63.
46.
Package insert. Prandin. Princeton, NJ: Novo Nordisk Pharmaceuticals, October 2002.
47.
Package insert. Precose. West Haven, CT: Bayer Corporation, May 2003.
48.
Package insert. Glucophage. Princeton, NJ: Bristol-Myers Squibb, April 2003.
49.
Package insert. Actos. Lincolnshire, IL: Takeda Pharmaceuticals America, July 2002.
50.
Package insert. Avandia. Research Triangle Park, NC: GlaxoSmithKline, March 2003.
51.
HollandEGYoungLY. Interpretation of clinical laboratory tests. In: Koda-KimbleMAYoungLY, eds. Applied therapeutics: The clinical use of drugs. 7th ed.Philadelphia: Lippincott Williams & Wilkins, 2001: 2–14.
MuellerMJ. Identifying patients with diabetes mellitus who are at risk for lower extremity complications: Use of Semmes—Weinstein monofilaments. Physical Therapy1996; 76: 68–71.
